AASLD 2017: Hepatitis C Testing Linked to Reduced Opioid Use
Getting tested for hepatitis C virus (HCV) was associated with reduced drug use, especially among those who tested positive, but evenpeople who tested negative saw some reduction, according to study results presented at the AASLD Liver Meeting in October in Washington, DC.
AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.
Web Design and Development by